Skip to main content

Table 3 Comparison between the improved patients group versus non-improved patients group regarding different assessed parameters

From: Efficacy of neural prolotherapy in treatment of meralgia paresthetica: a case series

Demographic, anthropometric and clinical characteristics; preinjection outcomes measures and procedure assessment Improved
patients group
(n = 12 lower limbs from 10 patients)||
Non-improved patients group
(n = 7 lower limbs from 5 patients)¶
Test of significance P
Age (year)† 44.50(43.75 ± 10.69) 39(38.42 ± 9.03) (Z) − 1.016 0.340
Women‡ 7(70) 4(80) (X2) 0.170 0.680
Weight (kg)† 93.25(90.37 ± 18.20) 78.00(84.78 ± 12.34) (Z) − 0.931 0.352
Height (cm)† 161(162.25 ± 7.27) 164(164.14 ± 4.18) (Z) − 0.764 0.445
BMI (kg/m2)† 34.66(34.19 ± 5.76) 31.24 (31.42 ± 3.94) (Z) − 1.270 0.204
BMI categories
Normal weight‡ 1(10) 0(0) (X2) 2.550 0.466
Overweight‡ 1(10) 2(40)   
Obesity‡ 7(70) 3(60)   
Morbid obesity‡ 1(10) 0(0)   
Side (right/left)§ 6/6(50/50) 4/3(57.1/42.9) (X2) 0.090 0.764
Duration of the symptoms (months)† 12(14.16 ± 9.55) 12(15.00 ± 9.60) (Z) − 0.043 0.967
Preinjection outcomes measures
Overall MP symptoms (VAS)† 7(7.08 ± 1.37) 7(6.85 ± 1.77) (Z) − 0.476 0.650
MP pain (VAS)† 5(5.75 ± 1.71) 7(7.57 ± 1.81) (Z) − 2.261 0.028*
MP paresthesia (VAS)† 7(6.91 ± 1.50) 8(8.00 ± 1.29) (Z) − 1.637 0.120
MP effect on function and QoL (VAS)† 5(5.50 ± 1.78) 6(5.71 ± 1.60) (Z) − 0.607 0.592
Procedure assessment
Immediately postinjection MP pain (VAS)† 0(0) 0(0) (Z) 0.000 1.000
Injection procedure-induced pain (VAS)† 2.75(2.54 ± 0.86) 2(2.28 ± 0.75) (Z) − 0.709 0.536
Presence of injection procedure side effects§ 1(8.3) 0(0) (X2) 0.616 0.632#
Receiving an extra-injection upon request§ 1(8.3) 4(57.1) (X2) 5.432 0.038*#
Degree of satisfaction regarding the procedure (VAS)† 9.50(9.16 ± 1.02) 4(4.42 ± 2.07) (Z) − 3.448  ≤ 0.0001*
  1. kg kilogram; cm, centimeter; BMI body mass index; m meter; MP meralgia paresthetica; VAS visual analogue scale; overall MP symptoms; patient assessment of overall MP symptoms; MP pain; patient assessment of MP pain; MP paresthesia; patient assessment of MP paresthesia; QoL quality of life; MP effect on function and QoL; patient assessment of MP effect on function and QoL; n number of lower limbs
  2. *P is significant at < 0.05
  3. Data are reported as median (mean ± standard deviation)
  4. Data are reported as number (percentage) of patients
  5. §Data are reported as number (percentage) of lower limbs
  6. ||Bilateral lower limbs with meralgia paresthetica were obtained from two patients (20%) among improved patients group
  7. Bilateral lower limbs with meralgia paresthetica were obtained from two patients (40%) among non-improved patients group
  8. #P value of Fisher's exact test